Newsroom

News & Press Releases


CeloNova BioSciences Inc. Named one of the Top 10 Cardiovascular Device Companies of 2019 by MedTech Outlook

San Antonio - April 5 2019

MedTech Outlook recognizes CeloNova BioSciences, Inc. as a pioneer at the forefront of cardiovascular innovation by naming the company as one of the top 10 cardiovascular companies of 2019.

CeloNova’s foundation of innovation has led to the successful manufacturing and marketing of a family of products, including the COBRA PzF NanoCoated Coronary Stent (NCS), based upon its proprietary Polyzene-F (PzF) nanocoating technology, a revolutionary surface coating designed to optimize implant interaction within the body.


Stent Thrombosis and Bleeding Highest within 30 Days of Procedure; Cobra PzF Stent Shows Promise as Means to Address

San Antonio - September 6 2018 - James Pitt (Dexur)

In Dexur’s national data, there were about 150,000 Percutaneous Cardiovascular Procedures With Coronary Artery Stent each year from 2013-2016 in Medicare-eligible inpatients. Stents are a diverse and fast-moving market. The most common devices are bare-metal or drug-eluting, but innovations like CeloNova’s polymer-coated Cobra PzF stent may have advantages for patients at high risk of bleeding. This advantage comes indirectly, through reducing the risk of stent thrombosis.


Browse Our Archives

COBRA PzF NanoCoated Coronary Stent @ TCT 2019

September 25-29, San Francisco, CA

TCT Number 941

Dr. Luc Maillard will be presenting a poster titled "MAPT (Mono Antiplatelet Therapy) as Regular Regimen After Cobra PzF™ NanoCoated Coronary Stent (NCS) Implantation" at TCT.

When: September 27, 2019
Where: Moscone South, Lower Level, Hall B-C
Time: 9:15-10:45 AM

Register Today